Search Results - "Oliai, Caspian"

Hyperbaric Oxygen Therapy for Radiation-Induced Cystitis and Proctitis by Oliai, Caspian, M.D, Fisher, Brandon, D.O, Jani, Ashish, M.D, Wong, Michael, M.D, Poli, Jaganmohan, M.D, Brady, Luther W., M.D, Komarnicky, Lydia T., M.D

“…Purpose To provide a retrospective analysis of the efficacy of hyperbaric oxygen therapy (HBOT) for treating hemorrhagic cystitis (HC) and proctitis secondary…”
Get full text

Clinical features of pseudocirrhosis in metastatic breast cancer by Oliai, Caspian, Douek, Michael L., Rhoane, Caelainn, Bhutada, Abhishek, Ge, Phillip S., Runyon, Bruce A., Wang, Xiaoyan, Hurvitz, Sara A.

“…Purpose Pseudocirrhosis has been demonstrated to mimic cirrhosis radiographically, but studies evaluating the pathophysiology and clinical features are…”
Get full text

Radioprotectants to reduce the risk of radiation-induced carcinogenesis by Oliai, Caspian, Yang, Li-Xi

“…Abstract Purpose: Development of radioprotective agents has focused primarily on cytoprotection from relatively high doses of therapeutic radiation and nuclear…”
Get full text

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL by Tabbara, Nadeem, Gaut, Daria, Oliai, Caspian, Lewis, Tara, de Vos, Sven

“…•Disease progression following anti-CD19 monoclonal antibody Tafasitamab treatment should not preclude subsequent anti-CD19 CART-cell therapy.•Previous studies…”
Get full text

Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo by Dolfi, Douglas V, Duttagupta, Priyanka A, Boesteanu, Alina C, Mueller, Yvonne M, Oliai, Caspian H, Borowski, Annie B, Katsikis, Peter D

“…Although much is known about the initiation of immune responses, much less is known about what controls the effector phase. CD8(+) T cell responses are…”
Get full text

Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation by Yang, Shangxin, Multani, Ashrit, Garrigues, Jacob M, Oh, Michael S, Hemarajata, Peera, Burleson, Taylor, Green, Nicole M, Oliai, Caspian, Gaynor, Pryce T, Beaird, Omer E, Winston, Drew J, Seet, Christopher S, Schaenman, Joanna M

“…Remdesivir is the first FDA-approved drug for treating severe SARS-CoV-2 infection and targets RNA-dependent RNA polymerase (RdRp) that is required for viral…”
Get full text

Effectiveness of Single-Fraction, Low-Dose, Bilateral Whole Lung Radiation Therapy for Diffuse Alveolar Hemorrhage Secondary to Extramedullary Hematopoiesis: A Case Report and Review of the Literature by Neilsen, Beth K., Sleightholm, Richard L., Gower, Arjan, Tsai, Steven C., Schiller, Gary J., Oliai, Caspian, Lee, Alan, Raldow, Ann, Tenn, Stephen, Venkat, Puja S.

Get full text

SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines by Bernetich, Matthew, Oliai, Caspian, Lanciano, Rachelle, Hanlon, Alexandra, Lamond, John, Arrigo, Stephen, Yang, Jun, Good, Michael, Feng, Jing, Brown, Royce, Garber, Bruce, Mooreville, Michael, Brady, Luther W

“…To report an update of our previous experience using stereotactic body radiation therapy (SBRT) for the primary treatment of prostate cancer, risk stratified…”
Get full text

How to address second and therapy‐related acute myelogenous leukaemia by Oliai, Caspian, Schiller, Gary

“…Summary Secondary acute myelogenous leukaemia (AML), as compared to de novo AML, occurs in the more elderly population, is independently more resistant to…”
Get full text

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma by Oliai, Caspian, de Vos, Sven

“…Introduction: Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19. L-MIND (NCT02399085) is an ongoing, open-label,…”
Get full text

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Secondary Central Nervous System Lymphoma by Gaut, Daria, Oliai, Caspian, Mead, Monica

“…Introduction: Aggressive non-Hodgkin's lymphoma (aNHL) with secondary central nervous system (sCNS) involvement has a poor prognosis. Studies have reported a…”
Get full text

Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series by Gaut, Daria, Oliai, Caspian, Mead, Monica

Get full text

Intravenous IL-1 Receptor Antagonist for Prevention of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome by Park, Sunmin, Hannigan, Christopher, Tuscano, Joseph M, Timmerman, John, Oliai, Caspian H.

“…Background and Significance: The management of toxicities from autologous CD19-directed chimeric antigen receptor (CAR) T cell therapy have evolved and the…”
Get full text

Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia by Levin-Epstein, Rebecca, Oliai, Caspian, Schiller, Gary

“…Opinion statement Acute myelogenous leukemia (AML) in the elderly is complex and has a poor prognosis, often characterized by higher risk cytogenetic and…”
Get full text

Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review by Howell, Grant, Oliai, Caspian, Schiller, Gary

“…Liposomal formulation of anthracyclines provide better systemic and organ-specific tolerance, with potential for less local tissue damage during extravasation…”
Get full text

Delayed immune tolerance through donor haematopoietic stem cell infusion 14 months after kidney transplantation by Lum, Erik L, Nassiri, Nima, Kogut, Neil, Oliai, Caspian, Raldow, Anne, Reed, Elaine F, Veale, Jeffrey L

“…Peripheral blood apheresis was followed by cell separation and processing; CD34+ and CD3+ cells were cryopreserved in preparation for infusion into the…”
Get full text

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization by Keiffer, Gina, Kaleka, Guneet, Oliai, Caspian, Wilde, Lindsay, Palmisiano, Neil, Kasner, Margaret

Get full text

Trial in Progress: Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at High Risk for Relapse by Gaut, Daria, Oliai, Caspian, Tsai, Steven, Huang, Chiung-Yu, Tuscano, Joseph, Eradat, Herbert, Schiller, Gary J.

Get full text

Trial in Progress: Tagraxofusp-Based Therapy to Eradicate Measurable Residual Disease of Acute Myelogenous Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation by Gaut, Daria, Oliai, Caspian, Tsai, Steven, Tseng, Chi-Hong, Logan, Aaron C., Schiller, Gary J.

Get full text

Real World Outcomes of Patients with Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation after Induction with Liposomal Daunorubicin-Cytarabine (CPX-351) by Kaleka, Guneet, Ngo, Dat, Yang, Dongyun, Mokhtari, Sally, Marcucci, Guido, Nakamura, Ryotaro, Pullarkat, Vinod, Oliai, Caspian H., Salhotra, Amandeep

“…Background: Liposomal Daunorubicin-Cytarabine (CPX-351 or Vyxeos), is approved for upfront treatment of adult and pediatric patients with secondary Acute…”
Get full text